Official Title: “Phase 4 Study of Once-Daily Inhaled Glucocorticosteroid Administration in Asthma Patients”

once-daily inhaled glucocorticosteroids treatment can sufficiently control airway inflammation in asthma patients.

Study Type: Observational

Study Design: Case-Crossover, Cross-Sectional

Intervention(s) in this Clinical Trial

• Drug: Budesonide,hydrofluoroalkane-beclomethasone dipropionate
  • receive twice-daily administration
• Drug: Budesonide,hydrofluoroalkane-beclomethasone
  • once-daily administration at bedtime

Arms, Groups and Cohorts in this Clinical Trial

• : 1
  • receive once-daily administration of inhaled glucocorticosteroids at bedtime
• : 2
  • receive twice-daily administration of inhaled glucocorticosteroids

Primary Measures

• once-daily administration of inhaled glucocorticosteroids can control airway inflammation
  • Time Frame: two-year
    

Inclusion Criteria:

• Receive ICS for one year or more, with no change in dose within the previous 8 weeks

Exclusion Criteria:

• Two or more courses of oral corticosteroid in the previous 12 months
• Admission to hospital due to asthma in the previous 6 months
• Admission to the intensive care unit due to asthma at any time in the past
• Current cigarette smoker.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: 80 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Hamamatsu University

Overall Clinical Trial Officials and Contacts

Kingo Chida, MD,PhD Study Chair Unaffiliated  

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00559689

Study ID Number: Hamamatsu-17-43

ClinicalTrials.gov Identifier: NCT00559689

Health Authority: Japan: Institutional Review Board